Amgen, Inc. Hits New 52-Week High of USD 390.14

Amgen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 390.14 on February 27, 2026. This achievement underscores the company's robust performance, particularly in comparison to the S&P 500, where Amgen has outpaced the index with a one-year performance of 27.38% against the S&P 500's 17.36%. With a market capitalization of USD 202,016 million, Amgen is classified as a large-cap company, reflecting its substantial presence in the market. The stock's price-to-earnings (P/E) ratio stands at 21.00, indicating a favorable valuation relative to its earnings. Additionally, the company boasts a commendable return on equity of 100.80%, showcasing its efficiency in generating profits from shareholders' equity. Amgen also offers a dividend yield of 1.90%, appealing to income-focused investors. The stock's journey from a 52-week low of USD 261.43 to its current high illustrates its strong recovery and growth trajectory within the competitive landscape of the biotechnology industry.